{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:22:05Z","timestamp":1783059725311,"version":"3.54.6"},"reference-count":24,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background<\/jats:bold>\n                    : Brentuximab vedotin (BV) is a targeted therapy for CD30\u2010expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T\u2010cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV\u2010induced skin rashes are less frequent and not well characterized.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients and Methods<\/jats:bold>\n                    : This study analyzed the clinical and histologic features of BV\u2010induced skin rashes over the past 5\u00a0years, focusing on patterns and severity across lymphoma types. We retrospectively reviewed cases from the Dermatology and Hematology Departments at Bologna and Ancona Universities, and we identified 20 eligible patients (13 males, 7 females, median age 59\u00a0years) with a Naranjo score \u2265\u00a05. Six had CTCL, and 14 had systemic lymphoma.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : Rashes appeared after a median of 3.5 BV cycles, presenting as eczematous (n\u00a0=\u00a011 patients), maculopapular (n\u00a0=\u00a03), or lichenoid (n\u00a0=\u00a06). Histology showed cytotoxic lichenoid infiltrates in lichenoid cases and spongiotic dermatitis in eczematous ones. CTCL patients experienced more severe reactions (50 % grade \u2265\u00a03) compared to systemic lymphoma patients (36.3 %). BV was discontinued in 10\u00a0cases, while others continued with dose adjustments and corticosteroids.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    : Lichenoid reactions were more common in CTCL, possibly due to BV's effects on the tumor microenvironment. Recognizing rash patterns may optimize care and minimize unnecessary treatment interruptions.\n                  <\/jats:p>","DOI":"10.1111\/ddg.70322","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:48:22Z","timestamp":1783057702000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The different face of skin\u2010rash induced by brentuximab vedotin"],"prefix":"10.1111","author":[{"given":"Alessandro","family":"Pileri","sequence":"first","affiliation":[{"name":"Dermatology Unit IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italy"},{"name":"Department of Medical and Surgical Sciences Alma Mater Studiorum University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6318-2739","authenticated-orcid":false,"given":"Tullio","family":"Brunetti","sequence":"additional","affiliation":[{"name":"Dermatology Unit IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italy"},{"name":"Department of Medical and Surgical Sciences Alma Mater Studiorum University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Rupoli","sequence":"additional","affiliation":[{"name":"AOU delle Marche, Hematology Department  Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9366-7813","authenticated-orcid":false,"given":"Gianluca","family":"Cafasso","sequence":"additional","affiliation":[{"name":"Dermatology Unit IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italy"},{"name":"Department of Medical and Surgical Sciences Alma Mater Studiorum University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Zengarini","sequence":"additional","affiliation":[{"name":"Dermatology Unit IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italy"},{"name":"Department of Medical and Surgical Sciences Alma Mater Studiorum University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9783-7864","authenticated-orcid":false,"given":"Staphano","family":"Cedirian","sequence":"additional","affiliation":[{"name":"Dermatology Unit IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italy"},{"name":"Department of Medical and Surgical Sciences Alma Mater Studiorum University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bardazzi","sequence":"additional","affiliation":[{"name":"Dermatology Unit IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Misciali","sequence":"additional","affiliation":[{"name":"Dermatology Unit IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Starace","sequence":"additional","affiliation":[{"name":"Dermatology Unit IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italy"},{"name":"Department of Medical and Surgical Sciences Alma Mater Studiorum University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Agostinelli","sequence":"additional","affiliation":[{"name":"Hematopathology Unit, Department of Experimental Diagnostic and Specialty Medicine, University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Goteri","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Public Health (DISBSP) Universit\u00e0 Politecnica delle Marche  Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Morsia","sequence":"additional","affiliation":[{"name":"AOU delle Marche, Hematology Department, Ancona, Italy; Department of Clinical and Molecular Science (DISCLIMO) Universit\u00e0 Politecnica delle Marche  Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"issue":"10168","key":"e_1_2_7_2_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30\u2010positive peripheral T\u2010cell lymphoma (ECHELON\u20102): a global, double\u2010blind, randomised, phase 3 trial","volume":"393","author":"Horwitz S","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hon.2963","article-title":"Brentuximab vedotin in the treatment of relapsed\/refractory CD30+ peripheral T\u2010cell lymphoma: A FIL phase 2 study","volume":"40","author":"Stefoni V","year":"2022","journal-title":"Hematol Oncol"},{"issue":"1","key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/jdv.18563","article-title":"Brentuximab vedotin in the treatment of cutaneous T\u2010cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry","volume":"37","author":"Muniesa C","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10094","key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30\u2010positive cutaneous T\u2010cell lymphoma (ALCANZA): an international, open\u2010label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince HM","year":"2017","journal-title":"Lancet"},{"issue":"32","key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II Investigator\u2010Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and S\u00e9zary Syndrome With Variable CD30 Expression Level: A Multi\u2010Institution Collaborative Project","volume":"33","author":"Kim YH","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"e_1_2_7_7_1","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/ijd.13696","article-title":"Brentuximab vedotin in CD30+ primary cutaneous T\u2010cell lymphomas: a review and analysis of existing data","volume":"56","author":"Enos TH","year":"2017","journal-title":"Int J Dermatol"},{"issue":"1","key":"e_1_2_7_8_1","first-page":"99","article-title":"Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides)","volume":"19","author":"Pileri A","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"issue":"9","key":"e_1_2_7_9_1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(18)30426-1","article-title":"Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single\u2010arm, phase 1\u20132 trial","volume":"19","author":"Cole PD","year":"2018","journal-title":"Lancet Oncol"},{"issue":"32","key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T\u2010Cell Lymphoma and Lymphomatoid Papulosis","volume":"33","author":"Duvic M","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"e_1_2_7_11_1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma","volume":"378","author":"Connors JM","year":"2018","journal-title":"N Engl J Med"},{"issue":"13","key":"e_1_2_7_12_1","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open\u2010label, dose\u2010escalation study","volume":"14","author":"Younes A","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9","key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"e738","DOI":"10.1111\/jdv.20557","article-title":"Multicentric case series: Clinical, trichoscopic and histological characterization","volume":"39","author":"Cavestany Rodr\u00edguez R","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.annonc.2019.10.001","article-title":"Relation of cetuximab\u2010induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE\u20103 (AIO KRK0306)","volume":"31","author":"Holch JW","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1111\/jdv.19801","article-title":"Clinicopathological definition, management and prognostic value of mogamulizumab\u2010associated rash and other cutaneous events: A systematic review","volume":"38","author":"Avallone G","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"e_1_2_7_16_1","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1093\/annonc\/9.suppl_5.S67","article-title":"BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group","volume":"9","author":"Diehl V","year":"1998","journal-title":"Ann Oncol"},{"issue":"1","key":"e_1_2_7_17_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0305-7372(82)80003-0","article-title":"ABVD chemotherapy in the treatment of Hodgkin's disease","volume":"9","author":"Bonadonna G","year":"1982","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/PSN.0000000000000077","article-title":"Chemotherapy and radiotherapy effects on the skin","volume":"34","author":"DeHaven C","year":"2014","journal-title":"Plast Surg Nurs"},{"issue":"4","key":"e_1_2_7_19_1","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10\u2010vcMMAE, an anti\u2010CD30\u2010monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco JA","year":"2003","journal-title":"Blood"},{"issue":"7","key":"e_1_2_7_20_1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.clml.2015.02.023","article-title":"Safety and efficacy of single\u2010agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma: experience with 27 patients","volume":"15","author":"Zinzani PL","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"20","key":"e_1_2_7_21_1","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","article-title":"Brentuximab Vedotin (SGN\u201035)","volume":"17","author":"Katz J","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"13","key":"e_1_2_7_22_1","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1182\/blood.V96.13.4307","article-title":"Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells","volume":"96","author":"Mir SS","year":"2000","journal-title":"Blood"},{"issue":"9","key":"e_1_2_7_23_1","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/PAS.0000000000002268","article-title":"Histopathologic and Clinical Characterization of Brentuximab Vedotin\u2010associated Rash","volume":"48","author":"Narala S","year":"2024","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"e_1_2_7_24_1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.soncn.2006.01.013","article-title":"Common side effects of anti\u2010EGFR therapy: acneform rash","volume":"22","author":"Sipples R","year":"2006","journal-title":"Semin Oncol Nurs"},{"issue":"5","key":"e_1_2_7_25_1","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1111\/jdv.18831","article-title":"Mogamulizumab\u2010associated rashes, their presentation and prognostic significance: a single\u2010centre retrospective case series analysis","volume":"37","author":"Pileri A","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.70322","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ddg.70322","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.70322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:48:25Z","timestamp":1783057705000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.70322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":24,"alternative-id":["10.1111\/ddg.70322"],"URL":"https:\/\/doi.org\/10.1111\/ddg.70322","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"2024-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ddg.70322"}}